46 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years https://www.fool.com/investing/2024/01/28/a-bull-market-is-here-2-stocks-to-buy-and-hold-for/?source=iedfolrf0000001 Jan 28, 2024 - These companies can perform well through this bull run and beyond.
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024 https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/?source=iedfolrf0000001 Dec 29, 2023 - There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Merck (MRK) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/01/merck-mrk-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 01, 2024 - MRK earnings call for the period ending December 31, 2023.
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/?source=iedfolrf0000001 Feb 08, 2024 - Investors are still excited about obesity treatments and weight-management drugs.
Top Research Reports for Merck, Equinor & Illinois Tool Works https://www.zacks.com/commentary/2196131/top-research-reports-for-merck-equinor-illinois-tool-works?cid=CS-ZC-FT-research_daily-2196131 Dec 11, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors https://www.zacks.com/stock/news/2198303/merck-mrk-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2198303 Dec 14, 2023 - Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198513 Dec 15, 2023 - Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897 Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049 Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156 Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.

Pages: 12345

Page 1>